Abstract

To evaluate point-of-care testing (POCT) for the potential early detection of biomarkers of Parkinson’s disease, a systematic investigation of portable and low-cost platforms is performed based on the Proton-enzyme-linked immunosorbent assay (Proton-ELISA) methodology. The detection of the α-synuclein antigen was first presented by biotin-relative linkers, and glucose substrate solution was first performed with a systematic experimental design to optimize the sensing results. All materials in this study are commercially available. Three different experiments with the partitional check were performed to investigate the Proton-ELISA platform, including proton catalyzed efficiency, blocking efficiency, and full Proton-ELISA procedure. The response time was selected as 15 min by the time-dependent curves of a full reaction. The limit of detection of conventional ELISA kits is 0.169 ng/mL, which is much lower than the Proton-ELISA results. The final response of the full Proton-ELISA procedure to pH changes was approximately 0.60 and 0.12 for α-synuclein antigen concentrations of 100 ng/mL and 4 ng/mL, respectively. With the partitional check, pH changes of pure glucose substrate and conjugated oxidase and interference of the nonspecific binding are 1.7 and 0.04, respectively. The lower pH changes far from the partitional check results can be concluded for the properties of glucose oxidase conjugation, including the isoelectric point and binding affinity modification by the testing environment. This preliminary guideline can be used as a lesson learnt to speed up following studies of the evaluation and optimization of other antigen detection. Therefore, Proton-ELISA can be suggested for some special applications with the help of custom-designed conjugation in the environment with less degradation or interference and a proper detection concentration range.

Highlights

  • IntroductionTo replace conventional laboratory-based testing [1,2,3,4]

  • For a better quality of life for more populations around the world, a facile, rapidly detectable, affordable, and portable platform for the quantitative detection of target species in clinical analyses and medical diagnostics is desirable in point-of-care testing (POCT)

  • Strong evidence can be provided for the correct setup of this standard protocol with a commercial kit. This behaviour results from the higher concentration of α-synuclein antigen, the higher concentration of horseradish peroxidase (HRP), and subsequent TMB action

Read more

Summary

Introduction

To replace conventional laboratory-based testing [1,2,3,4]. Parkinson’s disease is currently a high-impact neurodegeneration disease. The impact ratio in elderly people (e.g., >65 years old) is 2–3% and increases with age [5,6]. The cost of treatments or health care can increase dramatically once the progression becomes more serious. The total number of Parkinson’s disease patients in the United States was approximately 1 million in 2017, and the total economic burden was USD 51.9 billion [7]. In Europe, there are approximately 1.4 million Parkinson’s disease patients, and the average

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call